FDAsafety guidance77% confidence
FDA AP — RYALTRIS (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Roche; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA211746. Sponsor: GLENMARK SPECLT. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Neurology · Multiple Sclerosis
- Sub-indication
- General
Related signal: FDA Grants Priority Review for OCREVUS Supplemental Application